LobbyingAmerican Society for Reproductive Medicine lobbying by quarter
American Society for Reproductive Medicine's latest lobbying report covers Q2 2026, at $20K. The four quarters Q4 2025–Q3 2026 total $60K. Its first report covers Q4 2022; the issues it reports most are Health Issues.
American Society for Reproductive Medicine
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $60K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $0 | 1 |
| Q1 2023 | $0 | 1 |
| Q2 2023 | $0 | 1 |
| Q3 2023 | $0 | 1 |
| Q4 2023 | $0 | 1 |
| Q1 2024 | $0 | 1 |
| Q2 2024 | $0 | 1 |
| Q3 2024 | $0 | 1 |
| Q4 2024 | $0 | 1 |
| Q1 2025 | $0 | 1 |
| Q2 2025 | $0 | 1 |
| Q3 2025 | $0 | 1 |
| Q4 2025 | $20K | 1 |
| Q1 2026 | $20K | 1 |
| Q2 2026 | $20K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$60K · 15 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES15 reports
- SENATE15 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseAmerican Society for Reproductive Medicine | $60K | 15 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 08/03for Q2 | In-house | $20K |
| 05/06for Q1 | In-house | $20K |
| 01/12for Q4 2025 | In-house | $20K |
| 01/09for Q4 2025 | In-house | Under $5,000 |
| 25/10/09for Q3 2025 | In-house | Under $5,000 |
| 25/07/29for Q2 2025 | In-house | Under $5,000 |
| 25/05/12for Q1 2025 | In-house | Under $5,000 |
| 25/02/06for Q4 2024 | In-house | Under $5,000 |
| 24/11/05for Q3 2024 | In-house | Under $5,000 |
| 24/07/12for Q2 2024 | In-house | Under $5,000 |
| 24/04/18for Q1 2024 | In-house | Under $5,000 |
| 24/02/06for Q4 2023 | In-house | Under $5,000 |
| 23/10/10for Q3 2023 | In-house | Under $5,000 |
| 23/07/20for Q2 2023 | In-house | Under $5,000 |
| 23/05/04for Q1 2023 | In-house | Under $5,000 |
| 23/01/20for Q4 2022 | In-house | Under $5,000 |